Exane Derivatives’s Zymeworks ZYME Stock Holding History

Exane Derivatives’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-632	Closed	-$21.9K	–	1080
2021 Q2	$21.9K	Sell	632 -4,656	-88%	-$148K	0.01%	696
2021 Q1	$167K	Buy	5,288 +1,987	+60%	+$80.8K	0.05%	327
2020 Q4	$156K	Buy	3,301 +632	+24%	+$29.4K	0.05%	341
2020 Q3	$124K	Sell	2,669 -31	-1%	-$1.06K	0.04%	270
2020 Q2	$97.4K	Buy	+2,700	New	+$99.4K	0.03%	298

Other funds holding ZYME

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Exane Derivatives's ZYME Position: Q3 2021 in Review

Exane Derivatives sold out of Zymeworks (ZYME) in Q3 2021, closing a stake of 632 shares — an estimated $21.9K sold.

Exane Derivatives first reported a position in ZYME in Q2 2020 and held it in 5 quarters. The position peaked at $167K in Q1 2021. 123 funds tracked by Wall St. Rank hold ZYME as of Q3 2021.

Exane Derivatives reported no remaining Zymeworks position as of Q3 2021 after selling out during the quarter.
Exane Derivatives sold 632 Zymeworks shares in Q3 2021, an estimated $21.9K.
Exane Derivatives first reported a position in Zymeworks in Q2 2020 and held it in 5 quarters.
Exane Derivatives's Zymeworks position peaked at $167K in Q1 2021.
123 funds tracked by Wall St. Rank held Zymeworks as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.